Walleye Capital LLC Takes $3.20 Million Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Walleye Capital LLC purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the third quarter, HoldingsChannel.com reports. The institutional investor purchased 1,121,738 shares of the company’s stock, valued at approximately $3,197,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Xeris Biopharma by 7.3% during the 1st quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after acquiring an additional 519,897 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Xeris Biopharma by 188.5% during the third quarter. SG Americas Securities LLC now owns 60,202 shares of the company’s stock worth $172,000 after purchasing an additional 39,335 shares during the period. Simplicity Wealth LLC purchased a new position in Xeris Biopharma in the 2nd quarter valued at $27,000. Wealth Enhancement Advisory Services LLC acquired a new position in Xeris Biopharma in the 3rd quarter valued at $35,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Xeris Biopharma by 33.9% in the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock worth $3,041,000 after acquiring an additional 342,300 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on XERS. HC Wainwright boosted their price target on shares of Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a research note on Monday, November 11th. Piper Sandler downgraded Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Monday, November 11th.

Xeris Biopharma Stock Up 3.0 %

Shares of NASDAQ XERS opened at $3.38 on Tuesday. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.69 and a 52 week high of $3.64. The stock has a market capitalization of $503.89 million, a price-to-earnings ratio of -7.51 and a beta of 2.65. The firm has a 50-day moving average price of $3.07 and a 200 day moving average price of $2.64.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.